mFOLFOXIRI Plus Panitumumab Improves Overall Survival in RAS/BRAF Wild-Type mCRC
Key Clinical Summary:
- Design/Population: The phase 3 TRIPLETE trial randomized patients with RAS/BRAF wild-type metastatic colorectal cancer to first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab.
- Key Outcomes: Upfront mFOLFOXIRI plus panitumumab significantly improved overall survival despite no differences in objective response rate, progression-free survival, early tumor shrinkage, depth of response, or R0 resection rate.
- Clinical Relevance: Intensified triplet chemotherapy plus panitumumab confers a meaningful overall survival benefit over doublet therapy in RAS/BRAF wild-type metastatic colorectal cancer, without differences in postprogression treatment exposure between arms.
Veronica Conca, MD, University of Pisa, Italy, discusses final results from the phase 3 TRIPLETE study comparing first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab among patients with RAS/BRAF wild-type metastatic colorectal cancer.
The intensified triplet regimen significantly improved overall survival compared with the doublet regimen, despite no differences in response rate or progression-free survival. These findings support upfront mFOLFOXIRI plus panitumumab as a survival-improving strategy in this population.
Source:
Conca V, Rossini D, Antoniotti C, et al. Upfront modified FOLFOXIRI plus panitumumab for RAS/BRAF wild-type metastatic colorectal cancer: Final results of the phase III TRIPLETE study. J Clin Oncol. Published online: January 8, 2026. doi:10.1200/JCO-25-01337
